Factors associated with repeat rectal Neisseria gonorrhoeae and Chlamydia trachomatis screening following inconclusive nucleic acid amplification testing: A potential missed opportunity for screening


Autoři: Cheríe S. Blair aff001;  Omai B. Garner aff002;  Bettina Pedone aff003;  Sam Elias aff003;  W. Scott Comulada aff004;  Raphael J. Landovitz aff001
Působiště autorů: Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America aff001;  Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America aff002;  Arthur Ashe Student Health and Wellness Center, University of California, Los Angeles, California, United States of America aff003;  Department of Psychiatry and Biobehavioral Services, University of California, Los Angeles, California, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226413

Souhrn

Objective

Given rising incidence of Neisseria gonorrhoeae and Chlamydia trachomatis (GC/CT), development of efficacious screening strategies is critical to interruption of the infection cycle. However, a small proportion of nucleic acid amplification testing (NAAT) results are inconclusive—resulting in delays in diagnosis and treatment. As such, this study seeks to evaluate factors associated with inconclusive rectal GC/CT NAAT.

Methods

This is a retrospective chart review of individuals who received an inconclusive rectal GC/CT NAAT result at a single institution from 3/2016-6/2018. Inconclusive GC/CT NAAT was defined as presence of PCR amplification inhibitors using Roche Cobas v2.0 CT/NG assay. Clinical charts were abstracted for age, gender, HIV status, GC/CT (urogenital, rectal, pharyngeal) and syphilis screening results during the study period, clinic type (HIV clinic, university student health center, other), and whether repeat testing occurred within 6 months following an inconclusive result. Logistic regression analysis was used to calculate adjusted and unadjusted odds ratios of factors associated with receipt of repeat testing following an inconclusive rectal GC/CT NAAT result.

Results

During the study period, 6.1% (852/14,015) of rectal GC/CT NAAT were inconclusive for one or both of GC and CT. Among the 413 patients whose inconclusive rectal GC/CT NAAT results that were included in our analysis, 66.6% (275/413) received repeat testing within 6 months, of which 8.7% (24/275) were positive (compared to 5.4% positivity rate of all rectal samples). In multivariable analysis, individuals living with HIV had lower odds of receiving repeat testing following inconclusive rectal GC/CT NAAT compared to HIV uninfected individuals (adj OR 0.25; p = 0.001).

Conclusions

Despite being disproportionately affected by the STI epidemic, individuals living with HIV had 75% lower odds of receiving repeat testing following inconclusive rectal GC/CT NAAT compared to HIV-uninfected individuals, representing potentially missed opportunities for treatment and prevention of ongoing STI transmission.

Klíčová slova:

HIV epidemiology – Chlamydia infection – Nucleic acids – Rectum – Syphilis


Zdroje

1. CDC. Sexually transmitted disease surveillance 2017 2018 [Available from: https://www.cdc.gov/std/stats17/.

2. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1. 26042815

3. Gunn RA, O’Brien CJ, Lee MA, Gilchick RA. Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997–2003. Sex Transm Dis. 2008;35(10):845–8. doi: 10.1097/OLQ.0b013e318177ec70 18607315

4. Patton ME, Kidd S, Llata E, Stenger M, Braxton J, Asbel L, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD surveillance network, United States, 2010–2012. Clin Infect Dis. 2014;58(11):1564–70. doi: 10.1093/cid/ciu184 24647015

5. Bachmann LH, Johnson RE, Cheng H, Markowitz L, Papp JR, Palella FJ, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48(5):1827–32. doi: 10.1128/JCM.02398-09 20335410

6. Buckwalter S, Sloan L, Cunningham S, Espy M, Uhl J, Jones M, et al. Inhibition controls for qualitative real-time PCR assays: are they necessary for all specimen matrices? J Clin Microbiol. 2014;52(6):2139–43. doi: 10.1128/JCM.03389-13 24740078

7. Chernesky M, Jang D, Luinstra K, Chong S, Smieja M, Cai W, et al. High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J Clin Microbiol. 2006;44(2):400–5. doi: 10.1128/JCM.44.2.400-405.2006 16455891

8. Parra-Sánchez M, García-Rey S, Breval IZ-Y, Sierra-Atienza C, Bernal-Martínez S, Palomares-Folía JC. Evaluation of a dilution method for non-evaluable results in the detection of Chlamydia trachomatis and Neisseria gonorrhoeae with the Cobas 4800 platform. Enferm Infecc Microbiol Clin. 2017;35(6):364–6. doi: 10.1016/j.eimc.2015.06.017 26415750

9. de Waaij DJ, Dubbink JH, Peters RP, Ouburg S, Morré SA. Comparison of GMT presto assay and Roche Cobas 4800 CT/NG assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in dry swabs. J Microbiol Methods. 2015;118:70–4. doi: 10.1016/j.mimet.2015.08.020 26327539

10. Geelen TH, Rossen JW, Beerens AM, Poort L, Morré SA, Ritmeester WS, et al. Performance of Cobas 4800 and m2000 real-time assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis. 2013;77(2):101–5. doi: 10.1016/j.diagmicrobio.2013.06.020 23891224

11. Roche. Cobas Amplicor CT/NG test for Neisseria gonorrhoeae. 2004. Available from: https://www.fda.gov/media/74064/download

12. Hoover KW, Butler M, Workowski K, Carpio F, Follansbee S, Gratzer B, et al. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis. 2010;37(12):771–6. doi: 10.1097/OLQ.0b013e3181e50058 20585275

13. Flagg EW, Weinstock HS, Frazier EL, Valverde EE, Heffelfinger JD, Skarbinski J. Bacterial sexually transmitted infections among HIV-infected patients in the United States: estimates from the Medical Monitoring Project. Sex Transm Dis. 2015;42(4):171–9. doi: 10.1097/OLQ.0000000000000260 25763669

14. Berry SA, Ghanem KG, Mathews WC, Korthuis PT, Yehia BR, Agwu AL, et al. Gonorrhea and chlamydia testing increasing but still lagging in HIV clinics in the United States. J Acquir Immune Defic Syndr. 2015;70(3):275–9. doi: 10.1097/QAI.0000000000000711 26068721

15. Patel MR, Brooks JT, Tie Y, Garg S, Bradley H. Prevalence of gonorrhea and chlamydia testing by anatomical site among men who have sex with men in HIV medical care, United States, 2013–2014. Sex Transm Dis. 2018;45(1):25–7. doi: 10.1097/OLQ.0000000000000691 28876291

16. Jones J, Weiss K, Mermin J, Dietz P, Rosenberg ES, Gift TL, et al. Proportion of incident HIV cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis. Sex Transm Dis. 2019;46(6):357–63. doi: 10.1097/OLQ.0000000000000980 31095100

17. FDA. FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea.


Článek vyšel v časopise

PLOS One


2019 Číslo 12